

Breadcrumb

1. Home

Entity Print



Tobias Alexander
ADWP Chair (ELECTED APRIL 2024, PREVIOUS CHAIR: Raffaella Greco)
Germany

Major achievements

For autoimmune diseases (ADs) not sufficiently responding to state-of-the-art immunosuppressive or biologic therapies, haematopoietic stem cell transplantation (HSCT) has been successfully implemented as treatment option in carefully selected patients, with endorsement as standard indication for systemic sclerosis and multiple sclerosis from international societies, such as EULAR (Del Galdo et al., *Ann*

Rheum Dis. 2024) and ECTRIMS (Muraro et al., *Nat Rev Neurol.* 2025). The EBMT Autoimmune Diseases Working Party (ADWP) has been central to development of these approaches. Currently, 4656 patients have been reported to the EBMT registry (Fig. 1).




Figure 1: Auto-HSCT cases reported to the EBMT Registry

Recent achievements from our working party include a position paper developed in collaboration the Patient Advocacy Committee (PAC) and Nurses Group of the EBMT on **patient related outcome parameters to be considered in HSCT recipients for ADs** (Alexander et al., *J Allergy Clin Immunol Glob*. 2024). Furthermore, we conducted a **survey on the centre policy on ATG usage** (Ismail et al., *Bone Marrow Transplant.* 2024) as well as **monitoring and managing viral reactivations post-transplantation for ADs** (Alexander et al., *Bone Marrow Transplant.* 2025). In cooperation with the EBMT Chronic Malignancies Working Party, we retrospectively analysed the **outcome of patients with VEXAS syndrome undergoing allogeneic HSCT** (Gurnari et al., *Blood Advances.* 2024).

Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been successfully adopted in ADs. To this end, we published an expert-based position statement and clinical practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee on **innovative cellular therapies for ADs** (Greco et al, *EClinicalMedicine.* 2024) and provided an update

on the **role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in immune-mediated neurological diseases** (Brittain et al., *Ann Neurol.* 2024).

The ADWP is dedicated to promoting clinical activities, teaching and translational research on HCT together with innovative cellular therapies as AD treatment. We continued to expand the evidence-base and support best-practice with studies and guidelines, including significant collaborative outputs with the EBMT Working Parties, JACIE, Trainee Committee, PAC and Nurses Group. Education is central in ADWP activities, including an educational meeting on “Immunology and Cellular Therapies in Autoimmune Diseases” held in Milano (Fig 2.), and a harmonisation workshop on HSCT in rheumatic diseases that took place in Lille 2024. Moreover, a section specifically designed for ADs was developed within the EBMT e-learning platform with contributions from key experts in the field.



Joint Educational Meeting of the ADWP and CTIWP - Milan, Italy - 10-12 October 2024

Principal research studies

Comparison of Cyclophosphamide/ATG vs BEAM/ATG conditioning regimens in autologous HSCT for Multiple Sclerosis
Study type
Retrospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment
Autologous
Principal investigator
Riccardo Saccardi

Post AHSCT (Autologous Hematopoietic Stem Cell Transplantation) management for patients with systemic sclerosis: a prospective, non-interventional approach across Europe (NISSC-2)
Study type
Non-interventional Prospective Studies
Diseases

Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment
Autologous
Principal investigator
Pr Dominique Farge
Observational Study in Multiple Sclerosis patients treated with autologous hematopoietic stem cell Transplantation (OMST)
Study type
Non-interventional Prospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment
Autologous
Principal investigator
Riccardo Saccardi
Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Study type
Retrospective Studies
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment

Principal investigator

Tobias Alexander
CAR-T Cell Therapy in Autoimmune Diseases as Concomitant or Main Indication: a 2-step Joint Study on behalf of EBMT ADWP and CTIWP
Study type
Closed Survey/Study
Diseases
Auto immune disorders
Group
Autoimmune Diseases Working Party (ADWP)
Type of treatment
CAR T
Principal investigator
Raffaella Greco


Key publications

2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
Group
Autoimmune Diseases Working Party (ADWP)
Practice Harmonisation and Guidelines Committee
1st listed author
Raffaella Greco
Journal
EClinicalMedicine.
2024
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
Group
Autoimmune Diseases Working Party (ADWP)
Chronic Malignancies Working Party (CMWP)
1st listed author
Carmelo Gurnari
Journal
Blood Adv.
2024

The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Gavin Brittain
Journal
Ann Neurol.
2024
ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)
Group
Autoimmune Diseases Working Party (ADWP)
1st listed author
Azza Ismail
Journal
Bone Marrow Transplant.
2024
Patient-reported outcomes in HSCT for autoimmune diseases: Considerations on behalf of the EBMT ADWP, PAC, and Nurses Group
Group
Autoimmune Diseases Working Party (ADWP)
Patient Advocacy Committee
Nursing Research Committee
Nursing Scientific Committee
1st listed author
Tobias Alexander
Journal
J Allergy Clin Immunol Glob.
See the full list of the ADWP 2024 publications



Indicators




	2022	2023	2024
Oral presentations	22	16	**8**
Poster presentations	1	4	**1**
International educational events	3	3	**2**

Major educational events



Event

50th Annual Meeting of the EBMT



Kingdom

Event

9th International Transplant and Cellular Therapy Course



Event

Immunology and Cellular Therapies in Autoimmune Diseases

Oct 10, 2024 - Oct 12, 2024 / Milan, Italy
Discover more

Webinars and e-courses

HSCT in Autoimmune Diseases E-Course
Panel Discussion: Autologous HSCT in Multiple Sclerosis
VISIT THE ADWP WEBPAGE